ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

Pfizer acquires Therachon

by Lisa M. Jarvis
May 11, 2019 | APPEARED IN VOLUME 97, ISSUE 19

 

Capturing a clinical-stage treatment for a rare form of dwarfism, Pfizer will pay up to $810 million to acquire Therachon, which is based in Basel, Switzerland. The biotech’s investors will get $340 million up front, with the remainder depending on the successful development of TA-46, a recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy. The treatment has completed Phase I studies to treat children with achondroplasia, the most common genetic cause of short-limbed dwarfism. The deal does not include the short bowel syndrome treatment apraglutide, which Therachon will spin off into an independent company.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment